Martin S. Maron

38.6k total citations · 19 hit papers
307 papers, 22.3k citations indexed

About

Martin S. Maron is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Surgery. According to data from OpenAlex, Martin S. Maron has authored 307 papers receiving a total of 22.3k indexed citations (citations by other indexed papers that have themselves been cited), including 295 papers in Cardiology and Cardiovascular Medicine, 51 papers in Epidemiology and 38 papers in Surgery. Recurrent topics in Martin S. Maron's work include Cardiomyopathy and Myosin Studies (271 papers), Cardiovascular Function and Risk Factors (133 papers) and Cardiovascular Effects of Exercise (112 papers). Martin S. Maron is often cited by papers focused on Cardiomyopathy and Myosin Studies (271 papers), Cardiovascular Function and Risk Factors (133 papers) and Cardiovascular Effects of Exercise (112 papers). Martin S. Maron collaborates with scholars based in United States, Italy and Canada. Martin S. Maron's co-authors include Barry J. Maron, Ethan J. Rowin, John R. Lesser, James E. Udelson, Iacopo Olivotto, Christopher Semsarian, Mark S. Link, Warren J. Manning, Franco Cecchi and Susan A. Casey and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Martin S. Maron

288 papers receiving 21.7k citations

Hit Papers

Effect of Left Ventricula... 2003 2026 2010 2018 2003 2015 2012 2020 2005 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy
    2003 995 citations Martin S. Maron, Iacopo Olivotto et al. profile →
  2. New Perspectives on the Prevalence of Hypertrophic Cardiomyopathy
    2015 889 citations Martin S. Maron, Barry J. Maron et al. profile →
  3. Hypertrophic cardiomyopathy
    2012 822 citations Barry J. Maron, Martin S. Maron profile →
  4. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary
    2020 727 citations Mark S. Link, Martin S. Maron et al. profile →
  5. Acute and Reversible Cardiomyopathy Provoked by Stress in Women From the United States
    2005 725 citations Scott W. Sharkey, John R. Lesser et al. Circulation profile →
  6. Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction
    2006 692 citations Martin S. Maron, Iacopo Olivotto et al. Circulation profile →
  7. Recommendations and Considerations Related to Preparticipation Screening for Cardiovascular Abnormalities in Competitive Athletes: 2007 Update
    2007 678 citations Barry J. Maron, Martin S. Maron et al. Circulation profile →
  8. Natural History and Expansive Clinical Profile of Stress (Tako-Tsubo) Cardiomyopathy
    2010 617 citations Scott W. Sharkey, John R. Lesser et al. profile →
  9. Left Ventricular Remodeling in Heart Failure
    2011 552 citations Martin S. Maron, James E. Udelson et al. profile →
  10. Long-Term Effects of Surgical Septal Myectomy on Survival in Patients With Obstructive Hypertrophic Cardiomyopathy
    2005 536 citations Barry J. Maron, Iacopo Olivotto et al. profile →
  11. Genetics of Hypertrophic Cardiomyopathy After 20 Years
    2012 485 citations Barry J. Maron, Martin S. Maron et al. profile →
  12. Occurrence and Frequency of Arrhythmias in Hypertrophic Cardiomyopathy in Relation to Delayed Enhancement on Cardiovascular Magnetic Resonance
    2008 464 citations Barry J. Maron, Evan Appelbaum et al. profile →
  13. Hypertrophic Cardiomyopathy
    2014 451 citations Barry J. Maron, Iacopo Olivotto et al. profile →
  14. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
    2020 408 citations Mark S. Link, Martin S. Maron et al. profile →
  15. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy
    2020 376 citations Mark S. Link, Martin S. Maron et al. Circulation profile →
  16. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 3: Hypertrophic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy and Other Cardiomyopathies, and Myocarditis
    2015 301 citations Barry J. Maron, James E. Udelson et al. Circulation profile →
  17. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy
    2022 249 citations Barry J. Maron, Harry Rakowski et al. profile →
  18. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary
    2020 201 citations Mark S. Link, Martin S. Maron et al. Circulation profile →
  19. Management of Hypertrophic Cardiomyopathy
    2022 186 citations Barry J. Maron, Harry Rakowski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Martin S. Maron United States 72 21.1k 3.2k 3.0k 2.8k 2.4k 307 22.3k
Steve R. Ommen United States 70 20.3k 1.0× 3.0k 0.9× 3.6k 1.2× 2.7k 0.9× 2.5k 1.1× 319 21.8k
Iacopo Olivotto Italy 64 15.7k 0.7× 1.8k 0.6× 2.9k 0.9× 1.4k 0.5× 2.6k 1.1× 396 17.7k
Geneviève Dérumeaux France 53 9.6k 0.5× 2.1k 0.7× 3.3k 1.1× 2.9k 1.0× 1.1k 0.5× 219 13.4k
Harry Rakowski Canada 60 13.1k 0.6× 3.1k 0.9× 3.7k 1.2× 1.7k 0.6× 1.1k 0.5× 209 14.3k
Philippe Charron France 40 9.8k 0.5× 1.1k 0.4× 1.3k 0.4× 595 0.2× 3.0k 1.3× 163 11.0k
Olivier Dubourg France 47 6.7k 0.3× 1.7k 0.5× 1.2k 0.4× 1.1k 0.4× 1.8k 0.8× 203 9.7k
Masakazu Yamagishi Japan 49 4.8k 0.2× 4.6k 1.4× 1.4k 0.5× 1.9k 0.7× 1.7k 0.7× 428 11.8k
Michel Desnos France 42 5.6k 0.3× 3.2k 1.0× 674 0.2× 276 0.1× 3.2k 1.4× 147 9.5k
David Adams United States 65 11.1k 0.5× 5.3k 1.7× 5.9k 1.9× 1.6k 0.6× 4.8k 2.0× 400 18.6k
Sergio Mondillo Italy 48 6.9k 0.3× 1.7k 0.5× 694 0.2× 2.8k 1.0× 246 0.1× 289 8.5k

Countries citing papers authored by Martin S. Maron

Since Specialization
Citations

This map shows the geographic impact of Martin S. Maron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin S. Maron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin S. Maron more than expected).

Fields of papers citing papers by Martin S. Maron

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin S. Maron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin S. Maron. The network helps show where Martin S. Maron may publish in the future.

Co-authorship network of co-authors of Martin S. Maron

This figure shows the co-authorship network connecting the top 25 collaborators of Martin S. Maron. A scholar is included among the top collaborators of Martin S. Maron based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin S. Maron. Martin S. Maron is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aglan, Amro, et al.. (2025). Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy. International Journal of Cardiology. 426. 133082–133082.
2.
Massera, Daniele, et al.. (2025). Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5 Years. Journal of the American Heart Association. 14(2). e037639–e037639. 3 indexed citations
3.
Barriales‐Villa, Roberto, Pablo García‐Pavía, Iacopo Olivotto, et al.. (2025). Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 14(6). e038758–e038758. 5 indexed citations
4.
Masri, Ahmad, Sara Saberi, Martin S. Maron, et al.. (2025). Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta‐Analysis. Journal of the American Heart Association. 14(17). e039551–e039551.
5.
Sayed, Ahmed, Barry J. Maron, Ethan J. Rowin, & Martin S. Maron. (2025). Evidence of Declining Mortality Trends for Hypertrophic Cardiomyopathy in the United States and the Impact of the COVID‐19 Pandemic. Journal of the American Heart Association. 14(7). e037047–e037047.
6.
Sangha, Veer, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.. (2025). Identification of hypertrophic cardiomyopathy on electrocardiographic images with deep learning. Nature Cardiovascular Research. 4(8). 991–1000. 2 indexed citations
7.
Nakamori, Shiro, Jennifer Rodriguez, Long Ngo, et al.. (2024). Accelerated myocardial fibrosis in young to middle-aged patients with hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance. 26(2). 101072–101072. 1 indexed citations
8.
Rowin, Ethan J., Raymond H. Chan, Michael T. Chin, et al.. (2024). Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy. Journal of the American Heart Association. 13(10). e033565–e033565. 10 indexed citations
9.
10.
Fahmy, Ahmed S., et al.. (2022). Radiomics and deep learning for myocardial scar screening in hypertrophic cardiomyopathy. Journal of Cardiovascular Magnetic Resonance. 24(1). 40–40. 24 indexed citations
11.
Maron, Barry J., Martin S. Maron, Matthew J. Maurer, et al.. (2021). Cardiovascular Diseases That Have Emerged From the Darkness. Journal of the American Heart Association. 10(20). e021095–e021095. 6 indexed citations
12.
Carrick, Richard, Martin S. Maron, Arnon Adler, et al.. (2021). Development and Validation of a Clinical Predictive Model for Identifying Hypertrophic Cardiomyopathy Patients at Risk for Atrial Fibrillation: The HCM-AF Score. Circulation Arrhythmia and Electrophysiology. 14(6). e009796–e009796. 33 indexed citations
13.
Maron, Barry J., Ethan J. Rowin, Knarik Arkun, et al.. (2020). Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. The American Journal of Cardiology. 127. 135–138. 14 indexed citations
14.
Maron, Martin S., N.A. Mark Estes, Lori Lyn Price, et al.. (2019). Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. The American Journal of Cardiology. 123(11). 1859–1862. 23 indexed citations
15.
Maron, Barry J. & Martin S. Maron. (2016). Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 13(5). 1155–1165. 56 indexed citations
16.
Sharkey, Scott W., et al.. (2015). Clinical Profile of Patients With High-Risk Tako-Tsubo Cardiomyopathy. The American Journal of Cardiology. 116(5). 765–772. 32 indexed citations
17.
Maron, Martin S., Raymond H. Chan, Adam P. McGraw, et al.. (2013). Abstract 16910: Can Spironolactone Mitigate Myocardial Fibrosis and Alter Sudden Death Risk and Heart Failure Symptoms in Patients With Hypertrophic Cardiomyopathy?: A Prospective, Randomized Trial. Circulation. 128. 5 indexed citations
18.
Spoladore, Roberto, et al.. (2012). Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence. European Heart Journal. 33(14). 1724–1733. 127 indexed citations
19.
Maron, Martin S., Ethan J. Rowin, Susan A. Casey, et al.. (2011). Abstract 14156: Risk Stratification and Outcome of Patients with Hypertrophic Cardiomyopathy Over 60 Years of Age: Does Age Count?. Circulation. 124. 1 indexed citations
20.
Maron, Martin S., Iacopo Olivotto, Caitlin Harrigan, et al.. (2011). Mitral Valve Abnormalities Identified by Cardiovascular Magnetic Resonance Represent a Primary Phenotypic Expression of Hypertrophic Cardiomyopathy. Circulation. 124(1). 40–47. 285 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Steve R. Ommen Breakdown of academic impact, for papers by Iacopo Olivotto Breakdown of academic impact, for papers by Geneviève Dérumeaux Breakdown of academic impact, for papers by Harry Rakowski Breakdown of academic impact, for papers by Philippe Charron Breakdown of academic impact, for papers by Olivier Dubourg Breakdown of academic impact, for papers by Masakazu Yamagishi Breakdown of academic impact, for papers by Michel Desnos Breakdown of academic impact, for papers by David Adams Breakdown of academic impact, for papers by Sergio Mondillo
Rankless by CCL
2026